Introduction.
B-cell lymphoma 6 (BCL6) is a transcriptional repressor required for germinal center (GC) formation and maintenance during the humoral immune response but also has been implicated to play a role in lymphomas derived from GC B-cells. BCL6 was originally identified as a target of chromosomal translocations in diffuse large B-cell lymphoma (DLBCL) (~40%) and follicular lymphoma (5-10%) cancers. 1 Furthermore, in gain-of-function and loss-of-function studies, transgenic IµHA-BCL6 mice developed lethal DLBCL-like tumors 2 and BCL6 shRNA induced lethality in DLBCL cell lines, 3 respectively. Published studies from a BCL6 mutant knock-in mouse model provided insight on the physiological effects of targeting BCL6 but in the context of normal GC development. 4 Small molecule BCL6 inhibitors based on a promiscuous inhibitor class 5 and peptido-mimetic 6 inhibitors have been reported to lead to an anti-proliferative phenotype in DLBCL. Recently, a high affinity BCL6-binding peptide has been reported. 7 BCL6 has been proposed as an attractive cancer therapeutic target 8 but there is a need for potent and selective tools to improve understanding of the BCL6 inhibition phenotype in DLBCL. A homodimer of the N-terminal Broad-Complex, Tramtrack and Bric a brac (BTB) domain of BCL6 forms an extended groove which acts as a binding site for the corepressors silencing mediator for retinoid or thyroid-hormone receptors (SMRT), nuclear receptor corepressor (NCOR) and BCL6 corepressor (BCOR). 9, 10 The resulting protein-protein interaction (PPI) leads to the repression of genes through which the survival and proliferation effects of GC B-cells is allowed to progress. PPI inhibition provides a significant challenge within medicinal chemistry, 11 potentially explaining the lack of BCL6 inhibitors published to date. In this manuscript we describe how we identified and optimized inhibitors of the PPI between BCL6 and its corepressors to assess the impact of such inhibition on the proliferation of DLBCL cell lines.
Results and Discussion
Our lead generation strategy followed two parallel workstreams. Firstly, inspection of the structure of the BCL6 BTB domain homodimer in complex with the corepressors BCOR 12 and SMRT 13 revealed what we considered to be a druggable binding pocket along the binding groove. In the case of SMRT binding, Ile1428 and His1426 sidechains occupied this pocket but these interactions did not seem to fill the entirety of the available space. Thus, a virtual screen to identify compounds that could bind to this pocket was conducted. The first step was to dock 3000 fragment-sized molecules with molecular weight less than 250 Daltons (Schrödinger, Glide). These were used to map out affinity interactions in the binding site.
Several top-scoring fragment poses were identified and combined into a single 'virtual molecule' that was used to define the desired ligand shape and pharmacophore. The next step was to use this for a shape in complex with BCL6 BTB domain homodimer (selected residues shown from the former only).
Despite the weaker affinity of 2, it had a higher ligand efficiency 14 (LE) of 0.26 than 1 (LE = 0.17).
However, since the large di-substituted aryl group at the 5-position of 1 was not as buried as the rest of the molecule in the protein, this group could be removed to give 3 which attained affinity and LE in the same region as 2 ( Table 1) . Inspection of the crystal structure of 2 revealed that Arg24 appeared to form a cation-π interaction with the 5-pyridyl group and thus we postulated that a less planar ring system with a carboxylic acid group at this position could bind with higher affinity through an ionic interaction. The non-planar pyrrolidine analogue 4 was inactive in FRET but addition of a carboxylic acid in 5 did achieve measurable binding affinity. Likewise homologated acid 6 was measured with FRET affinity of 55 μM and although the LE is less than 0.3, an alternative measure of compound quality, ligand lipophilicity efficiency (LLE) 15 was significantly increased due to reduced lipophilicity. Our aim in subsequent optimization was to increase FRET affinity while maintaining LE around 0.3 and LLE above 5. Mean of at least 2 independent measurements unless otherwise stated. e using SPR pKd instead of FRET pIC50.
Further inspection of the crystal structures of 1 and 2 in BCL6 revealed that the ligands only partially occupied the binding pocket ( Figure 2 ). No solvent molecules were resolved in the remainder of the pocket for these structures, therefore 3D-RISM solvent analysis 16 (CCG, MOE) was used to predict and characterize the positions of solvent molecules within the site. This analysis showed a network of unstable water molecules in the upper half of the pocket, one of which formed a hydrogen bond with the NH backbone of Glu115. This water was predicted to have high occupancy (0.79) and low stability (∆Gbind = 2.5 kcal/mol) suggesting that displacement would result in an increase in ligand affinity. We rationalized that increasing the size of the 7-cyclopropylamino group and adding a hydrogen bond forming moiety to interact with Glu115 could increase affinity through both Van der Waals and hydrogen bonding interactions. A bicyclic lactam group was selected to fulfill these criteria and resulted in 7 with a 150-fold increase in binding affinity ( Table 2 ). The co-crystal structure of 7 and BCL6 revealed that the bicyclic lactam traversed the binding pocket and the lactam carbonyl formed a clear hydrogen bond with the Glu115 backbone NH as predicted ( Figure 3 ). The carboxylic acid of 7 was proximal to Arg24 but did not appear to have the most favorable directionality for an ionic interaction and the interaction appeared to be via a structural water molecule. Consequently, the smaller alcohol 8 was prepared in the expectation that a less ionic but still polar hydrogen bonding interaction could be realized and indeed affinity was maintained at 0.37 μM. The importance of either the acid in 7 or alcohol in 8 was confirmed by pyrrolidine 9 which lacked these groups and had approximately10-fold reduced affinity. not the lowest energy conformation of the isolated ligand, suggested that joining these two atoms with a linker could force the bioactive conformation of binding to BCL6 to be a more prevalent conformation.
A bis-ether linker of six atoms in length was modelled to bridge the desired space and macrocycles 10, 11 and 12 were prepared as the cyclized equivalents of 7, 8 and 9 respectively. Gratifyingly, in all three cases, greater than 100-fold increase in affinity was realized through macrocyclization (Table 2 ). An additional SAR observation was that the (5S)-methanol substitution in 11 gave 5-fold affinity increase over 5H analogue 12.
A crystal structure of 11 bound to BCL6 was obtained and a remarkably close overlay between the acyclic 7 and macrocyclic 11 was observed in what is presumed to be the bioactive conformation ( Figure 4 ). The atoms in common between 11 and 7 overlay almost perfectly (RMSD = 0.96Å), with the exception of the substituent alpha to the pyrrolidine N which has switched sides due to the geometry enforced by the macrocyclic linker. The alcohol now forms hydrogen bonds to a structural water, Arg28 and back onto a pyrimidine N of the ligand. The linker is well-defined in the electron density and sits in a solvent-exposed region, on top of the protein surface, close to Tyr58, but making no polar interactions. In order to evaluate the extent to which free molecules in solution are adopting the bioactive conformation, a NMR-conformational analysis study was conducted. This conformational analysis makes use of interproton distances derived from NOE based experiments 17 and fits the NMR data to ensembles of conformers, selecting those that show the highest agreement with the experimental NMR. 18 Following this approach, it was observed for compound 8 that the pyrrolidine hydrogens and the aromatic H from the pyrimidine presented broad signals in the 1 H NMR at rt, indicating the presence of a slow-intermediate exchange equilibrium between conformers affecting that part of the molecule, whereas the lactam ring showed sharp signals pointing to a fast rotation of the ring in solution. By heating the NMR sample to 70 °C, a fast exchange between conformations was achieved and all the NMR signals were sharpened up.
NMR data for 8 was acquired at the latter temperature as it gave optimal spectra for the conformational analysis study (see supporting information). The analysis yielded two main conformations in solution ( Figure 5 ) with a relative population of 60:40. The main conformation 8A shows a good overall overlay with the X-ray structure of 11 except for the orientation of the lactam ring, which is rotated 180 degrees with respect to the bioactive conformation of 11. The second conformer 8B presents the lactam ring in the bioactive conformation, but shows a rotation of the pyrrolidine group compared to the X-ray structure.
Therefore, the flexibility of the lactam and pyrrolidine rings prevent 8 from fully adopting the bioactive conformation. A similar NMR analysis was carried out for macrocycle 11. In this case, the 1 H NMR at room temperature showed a pattern of signals and J-couplings indicative of a rigid linker and no experiments were needed at high temperature for the conformational study. Two main conformations were found to be populated in solution at a ratio 79:18. Both show a good agreement with the bioactive conformation of the same molecule ( Figure 5 ), especially the most populated conformation 11A (79%) which shows a nearly perfect match with the X-ray structure, indicating that the molecule has already adopted in solution the bioactive conformation, hence explaining the 128-fold affinity increase on macrocyclization of 8 to
11.
It was expected that a variety of different linkers could enable the bioactive conformation to be obtained but that some linkers would have greater probability of achieving this. In order to try to predict promising linker structures a method was developed to examine the relationship between molecule conformation and affinity. There are various ways to computationally derive the conformational ensemble of a molecule. Standard rule-based methods tend to perform poorly with large rings as they fail to properly sample different conformations of the macrocycle. 19, 20 Instead, a hybrid simulated annealing / large-scale low-mode sampling method (Macrocycle Conformational Sampling, Schrödinger) was performed. To ensure comprehensive sampling, 10,000 simulated annealing runs were conducted, each with 10,000 sampling search steps and the RMSD threshold for duplicate removal set to 0.001. All generated conformations were retained and sampling was assumed complete such that the conformational ensemble is representative of the real solution conformation of the molecule. Superimposition of each conformation onto the known bioactive conformation of 7 (not including the linker) was conducted and the RMSD of each individual conformation from the known bioactive conformation was calculated. The distribution of RMSD from bioactive for the entire conformational population was thus derived. It should be expected that compounds with a high proportion of conformations close to the bioactive conformation will have higher affinity than compounds that with a lower proportion of such similar conformations.
This predictive relationship between conformation ensembles and affinity was examined for five representative compounds from the existing set (9, 11, 12) and new linkers (13 and 14). For each compound, a distribution of RMSD values for the conformational ensemble was observed, with a tendency to show a higher proportion at lower RMSD for higher affinity compounds. The fraction of the conformation population with RMSD < 0.5 Å to the bioactive was observed to have an approximately linear correlation with the affinity on a log scale ( Figure 6 ). Subsequently, we used this model to help prioritize further linker designs for synthesis. The amide linker 13 was predicted to have a lower fraction of conformational ensembles matching the bioactive conformation and indeed only resulted in a 14-fold affinity increase on macrocyclization.
In contrast, the fully saturated linker 14 was predicted to have a higher fraction of conformational ensembles matching the bioactive conformation and resulted in a 121-fold affinity increase. All these macrocycles met our desired LE and LLE criteria. It is worth noting that the bis-allyl compound 15 ( Figure 7) , which is the acyclic precursor to 11, had a FRET affinity of 0.15 μM, indicating that addition of alkyl groups alone does not generate an affinity increase unless they are joined to form a macrocycle. In acyclic compounds such as 8, free rotation of the pyrrolidine allows the chiral alcohol group freedom to occupy multiple conformations. Indeed, the enantiomer of 8 has a very similar binding affinity of 0.59 μM, indicating that either stereochemistry can adopt a conformation favourable to binding. When converted to a macrocycle such as 11, the rotation of the pyrrolidine is restricted and the chiral alcohol occupies a limited range of conformations which would be expected to show different SAR.
Consequently, we prepared a number of different chiral alcohol containing macrocycles to explore the effect on binding affinity for different positions of this group. This was completed in a simpler system without the lactam ( In an attempt to explain the origin of this increase, 3D-RISM solvent analysis was used to characterize solvent molecules. Analysis of the protein structure with 7, which does not contain the methanol moiety, predicts a stable structural water adjacent to the pyrimidine N and forming a bridging interaction to Arg28 (occupancy = 0.71, ∆Gbind = -0.98). The protein structure of 11 demonstrates that the (5S)-methanol group perfectly displaces this predicted water and replaces all these interactions, spanning both units of the BCL6 dimer, and thus provides an explanation for the observed increase in affinity. In our attempts to improve binding affinity to BCL6, we monitored the kinetics of binding with the aim of identifying compounds that had longer residence times and thus gave potential for longer lasting effects in cellular assays. 21 A selection of kinetic data is shown in Table 4 to illustrate our findings.
Gratifyingly, the binding affinity from SPR correlated very well with the affinity measured in FRET (R 2 = 0.99). As affinity was increased, the on and off-rate constants were not modulated equally ( Figure 8 ).
Addition of the lactam ring (purple arrow) gave a significant decrease in the off-rate constant and a smaller increase in on-rate constant. The transformation from acyclic to macrocycle (green arrows) gave a substantially greater decrease in off-rate constant compared to increase in on-rate constant. Addition of the (5S)-methanol (or (5S)-acetic acid) to a macrocyclic compound gave a substantial decrease in off-rate constant (pink arrows). Thus, the affinity increase observed on macrocyclization of 7 to 10 and 8 to 11
can be understood as a combination of two factors. Firstly, an on-rate constant increase due to a more rigid linker giving the preorganized binding conformation and secondly, the delivery of the (5S)-methanol or (5S)-acetic acid to a favorable position for multiple hydrogen bonding interactions hence giving an offrate constant decrease. Consequently, for the remainder of our optimization, the lactam ring, macrocycle and (5S)-methanol were retained. Table 4 . FRET affinity and binding kinetics for BCL6 of selected compounds
BCL6 SPR Figure 8 . On and off-rate constants for compounds in Table 4 . Arrows connect matched molecular pairs:
pink arrow indicates addition of (5S)-methanol or (5S)-acetic acid, green arrow indicates macrocyclization and purple arrow indicates addition of lactam ring.
Our original virtual screening hit 1 originated from an AstraZeneca project targeting the kinase CK2. 22 Thus we profiled our lead BCL6 macrocycle 11 across a panel of 126 kinases to understand kinase selectivity (see supporting information). Since we had already performed significant optimization for BCL6, we anticipated that CK2 activity would have been reduced. The only kinase to exhibit greater than 60% inhibition at 1 μM across the panel was indeed CK2 and this translated into a CK2 IC50 of 0.64 μM (220-fold margin vs BCL6). The original hit 1 had CK2 IC50 of 0.012 μM in the same assay, thus the CK2 activity had been reduced 50-fold. However, since the pyrazolo[1,5-a]pyrimidine core of our BCL6 binders had been common to a series of AstraZeneca CK2 inhibitors, we sought to further develop SAR against CK2. A crystal structure of 11 bound to CK2 was obtained which showed that the aniline NH of 11 formed a key hydrogen bond in both proteins ( Figure 9 ). In CK2, this interaction was with the hinge domain of the kinase (Val116) while for BCL6 a strong hydrogen bond to the carbonyl of Met51 was formed. While structurally quite different the binding pockets of BCL6 and CK2 exhibit similar interactions and 11 shows very similar bound conformations in each case: both show polar interactions for the lactam group and for the (5S)-methanol group, underlining the potential difficulty in obtaining selectivity over CK2. showing nearly identical binding modes.
As the 3-cyano group appeared to form a key interaction with Asp175 (via a bridging water molecule) in CK2 with no equivalent interaction in BCL6, we probed the SAR at this position (Table 5 ).
BCL6 affinity was highest for the 3-CN analogue 22 and when only a hydrogen was present at this position (23) BCL6 affinity was reduced 20-fold along with a loss of CK2 activity (>10 μM), as anticipated from structural analysis. Changing the 3-CN to 3-Cl in 24 resulted in similar BCL6 affinity with 3.5-fold reduction in CK2 activity, presumably due to the 3-Cl being unable to make the water mediated polar interaction with Asp175 in CK2. This led us to prefer the use of 3-Cl in subsequent analogues. Table 5 . SAR exploration at R3. Finally, the SAR around substitution of the lactam nitrogen (R4) was explored (Table 6 ). With high affinity BCL6 binders, we were able to demonstrate activity in a BCL6 cell reporter assay and develop cellular SAR. The unsubstituted analogue 25 exhibited high BCL6 affinity, weak CK2 activity and modest BCL6 cell activity (4.1 μM). The measured intrinsic permeability of 25 in a Caco-2 assay was measured to be high (Papp = 46 x 10 -6 cm·s -1 ) and in a bidirectional Caco-2 efflux assay the efflux ratio was measured to be 1.4. Aqueous solubility of 25 was measured as 31 μM thus it was difficult to attribute a physicochemical reason for the large drop-off from binding affinity to cellular activity against BCL6.
We believed it was likely that although the FRET binding affinity is a direct measure of affinity to the BCL6 BTB domain homodimer, this assay may not be fully representative of the binding of compound to BCL6 within a complex cellular environment in the presence of endogenous corepressors.
Consequently, although we wished to maintain high FRET affinity, our focus was to develop SAR and increased potency against the BCL6 cell reporter assay.
Lipophilic groups of increasing size at R4 maintained high affinity for BCL6 while maintaining CK2 activity above 1 μM (26 -28). Notably, the largest of these, containing the di-fluorocyclobutyl group (28), gave a 10-fold increase in BCL6 cell potency. Analysis of all BCL6 crystal structures could not rationalize a binding interaction between the di-fluorocyclobutyl group and protein as it would be expected to occupy a solvent accessible space. Encouraged by the cell potency of this group, carboxylic acid 29 with the same R4 was prepared but BCL6 affinity and cell potency decreased 3-fold and 6-fold respectively and CK2 activity was increased 13-fold. The acid side-chain of Glu115 exists on the BCL6
homodimer surface and compound 30 with a basic sidechain was designed to make an interaction with this acid. High BCL6 affinity was observed for 30 but the cell activity remained above 1 μM. Thus we returned to lipophilic R4 groups and a range of benzylic compounds (31-36) were prepared. All these benzyl compounds had similar BCL6 binding affinity of around 0.01 μM and showed no activity against CK2 when a 3-Cl substituent was employed. Comparison of 3-Cl 32 with 3-CN 33 highlighted that even in these optimized compounds the 3-CN substituent still produced some weak CK2 activity. Submicromolar BCL6 cell potency with SAR was observed for all these benzyl compounds irrespective of All compounds tested in the BCL6 cell reporter assay were also tested in a PLZF cell reporter assay to rule out pan-BTB domain protein activity. All compounds were inactive (>30 μM) in the PLZF assay. Compound 31 was selected from our set of potent cell active BCL6 inhibitors and profiled across a panel of 398 kinases screened at 1 μM at ThermoFisher. No activity above 70% was detected for any kinase (see supporting information). Furthermore, in vitro pharmacological profiling 23 of 31 against a panel of over 30 diverse targets was conducted and exhibited a good selectivity profile (see supporting information) with only two targets showing activity below 1 μM (GABA receptor, Ki = 0.25 μM; 5-hydroxytryptamine receptor 1B, EC50 = 0.57 μM). This profiling led us to conclude that we had achieved our aim to develop highly selective cell potent BCL6 inhibitors.
Antiproliferative activity
DLBCL cell lines have been classified as BCL6 dependent or independent on the basis of whether they are affected by BCL6 inhibition or knockdown. 3, 5, 6 We sought to examine the antiproliferative activity of our BCL6 inhibitors in a range of DLBCL cell lines (both GCB and ABC subtypes) based on this classification of BCL6 dependent (e.g. OCI-Ly1, SUDHL-4, OCI-Ly3, SUDHL2, U-2932, OCI-Ly10, TMD8) and BCL6 independent (e.g. Karpas 422, OCI-Ly19) lines (Table 7 ). In addition, we included a multiple myeloma (MM) cell line as a cell line that we expected to be insensitive to BCL6 inhibition given that MM lines derive from post GC-B cells and generally express weak or undetectable levels of BCL6.
24
FX1 displayed weak antiproliferative activity across the entirety of our cell panel.
We hoped that as we tested increasingly more potent and selective BCL6 inhibitors, a clear pattern of inhibition dependent on sensitivity to BCL6 would emerge. However, as illustrated in Figure 10 , weak antiproliferative activity was consistently observed across the entirety of the cell panel. Those DLBCL cell lines previously defined as BCL6 sensitive did not show any difference from those defined as insensitive and the pattern of activity in the MM line was also similar. This leads us to conclude that the inhibition of BCL6 is either not relevant for proliferation of these DLBCL lines or that the effect is too weak to be of significance.
Consequently, we conclude that the BCL6 hypothesis as a means of treatment for DLBCL is still unproven and we have elected not to progress this series of BCL6 inhibitors further into development. Figure 10 . Plot of proliferation pGI50 variation with BCL6 cell pIC50 for compounds in Table 7 (FX1 is marked by a diamond, AstraZeneca compounds by circles and each compound is a different colour)
Synthesis
Aromatic nucleophilic substitution of the corresponding 5,7-dichloropyrazolopyrimidines with nitrogen nucleophiles was a key reaction for efficient assembly of all BCL6 inhibitors prepared during this work.
For example, in a simple one-pot procedure, dichloropyrazolopyrimidine 37 reacted first with 6-amino- Alternatively, we developed a novel strategy for the construction of diverse macrocyclic motifs.
Our new approach was based on the double aromatic nucleophilic substitution reaction between preassembled masked di-nucleophiles (e.g. 47) with corresponding heterocyclic di-electrophiles (37 or 48, and 30-36) were synthesized from the aniline 62 using our preferred SNACK approach. 
Conclusion
Starting with a fragment screen and virtual screen we identified weak hits targeting the PPI interaction between BCL6 and its corepressors. Using SBDD, binding affinity was increased 100,000-fold. This involved displacing binding site water, forming new ligand-protein interactions and a macrocyclization to favour the bioactive conformation of the ligands. Optimization for slow-off rate constant kinetics was conducted as well as improving selectivity against an off-target kinase, CK2. Potency in a cellular BCL6 assay was further optimized to afford highly selective probe molecules. Anti-proliferative activity was assessed across a number of DLBCL lines, and a MM cell line. Despite increasing BCL6 potency, only weak anti-proliferative effects were observed across the cellular panel with no clear relationship to BCL6 sensitive or insensitive lines. As a result, we conclude that the BCL6 hypothesis as a means of treatment for DLBCL remains unproven.
Experimental Section
General. All solvents and chemicals used were reagent grade. Anhydrous solvents THF, DCM and DMF were purchased from Aldrich. Flash column chromatography was carried out using prepacked 
8-Hydroxy-6-nitro-3,4-dihydroquinolin-2(1H)-one (44)
A solution of K2CO3 (2M in water) (216 mL, 431 mmol) was added to 38 (90 g, 360 mmol) in MeOH (1 L) and the resulting mixture was stirred for 10 min. 
tert-Butyl (2S,4S)-4-(((E)-4-bromobut-2-en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (46)
50% Sodium hydroxide solution (10 mL) was added to a vigrously stirred solution of tert-butyl (2S,4S)- 
(2S,4S)-tert-Butyl 4-(((E)-4-((6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)oxy)but-2-en-1-yl)oxy)-

2-((trityloxy)methyl)pyrrolidine-1-carboxylate (47)
A mixture of 44 (2.0 g, 14.5 mmol), 46 (1.83 g, 3.09 mmol) and DMF (15 mL) was stirred at 80 °C for 75 min. After cooling to rt the mixture was diluted with EtOAc (250 mL) and the solid was filtered off.
The filtrate was washed with 1M citric acid (25 mL), water (2 x 25 mL) and saturated brine (25 mL). The organic layer was dried over Na2SO4, filtered and evaporated to afford a residue which was purified by flash silica chromatography, elution gradient 0 to 70% EtOAc in heptane to afford the title compound (2.14 g, 96%) as a pale yellow solid. 1 
(2S,4S)-tert-Butyl 4-(((E)-4-((6-amino-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)oxy)but-2-en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate
Iron powder (0.366 g, 6.56 mmol) was added to 47 (787 mg, 1.09 mmol) and ammonium chloride (41 mg, 0.77 mmol) in EtOH (15 mL) and water (5 mL). The resulting mixture was stirred at 60 °C for 4 h.
The reaction mixture was evaporated to dryness, redissolved in EtOAc (100 mL), and washed sequentially with water (2 x 100 mL) and saturated brine (100 mL). The organic layer was dried with MgSO4, filtered and evaporated to afford the title compound (727 mg, 96%) as a yellow foam. mmol) and DIPEA (0.183 mL, 1.05 mmol) in EtOH (3.5 mL). The resulting mixture was stirred at 60 °C for 4 h and then evaporated to dryness. The residue was dissolved in DCM (3.5 mL) and TFA (3.5 mL)
was added slowly. The mixture was stirred for 3 h and then evaporated to dryness. The residue was dissolved in DCM (3.5 mL) and added to DIPEA (1.83 mL, 10.5 mmol) and n-butanol (35 mL) at 130
°C. The mixture was heated for 4 h and then cooled to rt. The reaction mixture was evaporated to dryness and redissolved in EtOAc (25 mL), and washed sequentially with water (25 mL) and saturated brine (25 mL). The organic layer was dried with MgSO4, filtered and evaporated to afford a residue which was purified by flash silica chromatography, elution gradient 0 to 5% MeOH in DCM to afford a yellow residue. This was triturated with tert-butyl methylether to give a solid which was collected by filtration and dried under vacuum to give the title compound as a yellow powder (78 mg, 46% the mixture was stirred at rt for 1 h. The mixture was evaporated to dryness to afford the uncyclized product as gum which was transferred into a microwave vial and n-butanol (20 mL) and DIPEA (0.6 mL, 3.44 mmol) were added. The mixture was stirred at 140 °C within the microwave reactor for 3 h and cooled to rt. The solvent was evaporated in vacuo to yield crude product which was purified by preparative HPLC (Waters XSelect CSH C18 column, 5µ silica, 30 mm diameter, 100 mm length), using decreasingly E)-4-((6-amino-1-(3-methoxybenzyl)-2-oxo-1,2,3,4-tetrahydroquinolin-8 h and cooled to rt. The solvent was evaporated in vacuo to yield crude product which was purified by preparative HPLC (Waters XSelect CSH C18 column, 5µ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH3) and acetonitrile as eluents to afford the title compound (137 mg, 42%) as a tan solid. 
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Biological Protocols:
Cloning, expression and purification of human BCL6 BTB domain
The gene sequence encoding BCL6 BTB domain (5-129) 13 was customer-synthesized with N-terminal 
BCL6 SPR assay:
Biacore 4000 or T200 instruments (GE Healthcare) were used to monitor binding interactions via SPR. 
BCL6 2D NMR assay
NMR spectra were acquired at 300 K with a 600 MHz NMR instrument (Bruker, Billerica MA) equipped with an AVANCE III console and a triple-resonance cryogenic probe. Samples were at pH 7.0 in a 50 mM sodium phosphate buffer containing 400 mM sodium chloride, and 5% deuterium oxide. The 
